What is Patheon Pharma Services?
Headquartered in Durham, North Carolina, and established in 1974, Patheon Pharma Services operates as a sophisticated contract development and manufacturing organization (CDMO). The company specializes in the end-to-end production of active pharmaceutical ingredients (APIs), oral solid doses, sterile injectables, and specialized gel formulations. By providing essential infrastructure for drug development, Patheon enables pharmaceutical innovators to accelerate their time-to-market while maintaining rigorous quality standards. Its market position is defined by its ability to handle high-complexity manufacturing requirements, serving as a vital partner for both emerging biotech firms and established multinational pharmaceutical corporations.
How much funding has Patheon Pharma Services raised?
Patheon Pharma Services has raised a total of $625M across 1 funding round:
Stock Offering
$625M
Stock Issuance/Offering (2016): $625M, investors not publicly disclosed
Key Investors in Patheon Pharma Services
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Patheon Pharma Services?
With the recent injection of capital, Patheon Pharma Services is well-positioned to enhance its operational footprint and technological infrastructure. The strategic focus will likely center on expanding capacity for sterile manufacturing and advanced drug delivery systems, which are currently in high demand across the global healthcare sector. By leveraging this financial backing, the company aims to optimize its manufacturing processes, potentially integrating more automated, data-driven quality control systems to meet evolving regulatory requirements. As the pharmaceutical industry shifts toward more personalized medicine and complex biologics, Patheon's ability to scale its specialized production capabilities will be a key driver of its long-term growth and competitive advantage in the global CDMO market.
See full Patheon Pharma Services company page
